Open access

769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma
Jessica SW Borgers, Divya Lenkala, Brian McCarthy, Victoria Kohler, Sebastian Hymson, Emily Jackson, Katya Esaulova, Joong Hyuk F Sheen, Olivia Finney, Kristen Balogh, Sebastian Klobuch, Matthijs D Linssen, Cynthia Nijenhuis, Richard B Gaynor, Mark DeMario, John B Haanen, Marit MVan Buuren

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A864; DOI: 10.1136/jitc-2023-SITC2023.0769
770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients
Guillemo De Velasco Oria de Rueda, Piotr Rutkowski, Michele Maio, Ana Maria Arance, Caroline Robert, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Jessica Kundapur, Julien Villaudy, Hans Van Eenennaam, Laura Lassouw-Polman, Alexander Eggermont

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A865; DOI: 10.1136/jitc-2023-SITC2023.0770
771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors
Adi Diab, Anthony El-Khoueiry, Reham Abdel-Wahab, Sajeve Thomas, Evan Hall, Kaida Wu, Benjamin S Maciejewski, Naveen K Mehta, Laura Liu, Jennifer S Michaelson, Jeffrey A Jones, Randy Sweis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A866; DOI: 10.1136/jitc-2023-SITC2023.0771
772 Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy
Bently Doonan, Christiana Shaw, Ji-Hyun Lee, Eugenio Manso, Hector Mendez-Gomez, Christina Von Roemeling, Duane A Mitchell, Elias Sayour

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A867-A869; DOI: 10.1136/jitc-2023-SITC2023.0772
773 A phase I/II study to evaluate the safety, tolerability and preliminary efficacy of GLS-012 monotherapy and in combination with zimberelimab in patients with advanced melanoma (Triumph-01)
Jun Guo, Lu Si, Jiman Zhu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A870; DOI: 10.1136/jitc-2023-SITC2023.0773
499 Myeloid diversity in hormone receptor positive breast cancer reveals myeloid and lymphoid signaling pathways that correlate with T cell inhibition
Chenyi Gu, Kenichi Shimada, Lukas Kania, Daniel E Michaud, Madeline G Townsend, Jennifer L Guerriero

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A561; DOI: 10.1136/jitc-2023-SITC2023.0499
501 AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity
Des C Jones, Lorraine Irving, Becki Dudley, Marcin Wolny, Seraina Blümli, Ellie Chatzopoulou, Alan Sandercock, Georgina Bowyer, Stacy Pryts, Kathy Mulgrew, Simon Dovedi, Fernanda Arnaldez, Mark Cobbold

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A562; DOI: 10.1136/jitc-2023-SITC2023.0501
502 Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy
Hang Ke, Faming Zhang, Jialing Li, Dawei Chen, Feiyu Peng, Cen Chen, Henry Li

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A563; DOI: 10.1136/jitc-2023-SITC2023.0502
503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles
Xiao Ke, Yonghao Zhao, Pengfei Ren, Gang Lei, Menglong Guan, Pengfei Wu, Ju Yue, Jichao Wang, Yanhua Xu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A564-A566; DOI: 10.1136/jitc-2023-SITC2023.0503
504 Anti-cancer activities of EU103 in a preclinical model of ovarian cancer
Hye Jeong Kim, Kyung-jung Kang, Jeamin Shin, JoongWon Lee, Byoung-Gie Kim, Byoung Kwon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A567; DOI: 10.1136/jitc-2023-SITC2023.0504

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages